Tesamorelin: the science of a growth hormone releasing peptide

What is tesamorelin?

Tesamorelin is a stabilized analog of growth hormone releasing hormone (GHRH), marketed as Egrifta and Egrifta WR. It is FDA approved for one specific use: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is the only FDA-approved medicine for that condition, and the F8 formulation, Egrifta WR, was approved in 2025.

Like sermorelin, it works upstream, prompting your own pituitary to release growth hormone rather than replacing it. Outside its approved indication, any use for general body composition, muscle, or anti-aging is off-label, which means it is not an approved or established use, and a provider weighs that carefully.

At Expert Health, tesamorelin is prescribed by a US-licensed provider and compounded by an FDA-regulated pharmacy. Its only FDA-approved use is HIV-associated lipodystrophy; other uses are off-label. Compounded medications are not FDA-approved. See the disclaimer below.

How tesamorelin works

Tesamorelin binds GHRH receptors in the pituitary and stimulates the release of growth hormone, which raises IGF-1. In its approved population, this leads to a selective reduction in visceral fat, the deeper abdominal fat that sits around the organs.

• Stimulates your own growth hormone through the GHRH pathway.
• Targets visceral fat in its approved indication, rather than fat overall.
• Keeps natural feedback, since the pituitary still regulates the release.

What the research shows

Tesamorelin's approval rests on solid trials. In the pivotal phase 3 study (Falutz and colleagues, published in The New England Journal of Medicine in 2007, around 400 participants), tesamorelin reduced visceral abdominal fat by about 15% over 26 weeks, while visceral fat rose slightly on placebo, with improvements in some lipid markers.

That evidence is specific to adults with HIV-associated lipodystrophy. For other goals, the data is far more limited, which is exactly why honest framing and provider oversight matter. Trial averages are not promises, and individual results vary.

Who it's for

Tesamorelin is a provider-guided treatment. Its clearest, evidence-backed use is in adults with HIV-associated lipodystrophy. Any other use is off-label and requires a careful conversation with a provider about what is and isn't established. A provider reviews your history and goals and confirms whether it is appropriate.

Safety and side effects

Common side effects include injection site reactions, joint pain, and swelling in the limbs. Because it raises growth hormone activity, it can affect blood sugar, so a provider screens and monitors for that. It is not appropriate for people with active cancer or certain other conditions, which is why provider oversight is essential and this should never be a gray-market purchase.

Frequently asked questions

Sources

1. Egrifta WR (tesamorelin for injection) Prescribing Information · U.S. FDA Label
2. FDA Approval of EGRIFTA WR (tesamorelin F8) for HIV-associated lipodystrophy · Theratechnologies / EATG